Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13221011 | 0.88 | HDAC6 (0.56) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL13203541 | 0.88 | HDAC6 (0.56) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL13220946 | 0.86 | BRD4 (0.58) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL13203552 | 0.86 | HDAC6 (0.54) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL13203549 | 0.84 | HDAC6 (0.53) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL13203545 | 0.84 | KDM4E (0.59) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL13221021 | 0.84 | HDAC6 (0.52) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL13203544 | 0.83 | HDAC6 (0.52) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL13220950 | 0.83 | HDAC6 (0.58) | HDAC6HDAC3HDAC1HDAC8HDAC2 | |
| SCHEMBL13203499 | 0.79 | NPC1 (0.68) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777051-B2 | Asymmetric benzimidazoles and related compounds as potassium channel modulators | ICAGEN, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7777051-B2 | Asymmetric benzimidazoles and related compounds as potassium channel modulators | ICAGEN, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20050038067-A1 | Asymmetric benzimidazoles and related compounds as potassium channel modulators | ICAGEN, INC. (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2005002503-A2 | ASYMMETRIC BENZIMIDAZOLES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038067-A1 | Asymmetric benzimidazoles and related compounds as potassium channel modulators | KCNJ2, KCNJ1, KCNJ11 | HDAC6 447/4885HDAC3 262/4885HDAC1 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.